Cargando…

Challenges in the Treatment of Glioblastoma by Chimeric Antigen Receptor T-Cell Immunotherapy and Possible Solutions

Glioblastoma (GBM), one of the most lethal brain cancers in adults, accounts for 48.6% of all malignant primary CNS tumors diagnosed each year. The 5-year survival rate of GBM patients remains less than 10% even after they receive the standard-of-care treatment, including maximal safe resection, adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Peng, Zhang, Yang, Ji, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300859/
https://www.ncbi.nlm.nih.gov/pubmed/35874698
http://dx.doi.org/10.3389/fimmu.2022.927132

Ejemplares similares